Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Proguanil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.39 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.39 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.39 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.39 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.38 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proguanil SCHEMBL45726 | 0.98 | LMNA (0.41) | LMNAMEN1KMT2AALDH1A1CNR1 | |
| Proguanil SCHEMBL2543837 | 0.97 | LMNA (0.40) | LMNAMEN1KMT2AALDH1A1CNR1 | |
| Proguanil SCHEMBL9247094 | 0.92 | MEN1 (0.40) | LMNAMEN1KMT2AALDH1A1CNR1 | |
| Proguanil SCHEMBL2539379 | 0.91 | MEN1 (0.46) | LMNAMEN1KMT2AALDH1A1CNR1 | |
| SCHEMBL1989233 | 0.90 | ALDH1A1 (0.44) | LMNAMEN1KMT2AALDH1A1CNR1 | |
| Proguanil SCHEMBL2545386 | 0.88 | ALDH1A1 (0.43) | LMNAMEN1KMT2AALDH1A1CNR1 | |
| Hydrochloric Acid SCHEMBL13584911 | 0.86 | NPC1 (0.48) | LMNAMEN1KMT2AALDH1A1EPHX1 | |
| SCHEMBL2350583 | 0.84 | ALDH1A1 (0.49) | LMNAMEN1KMT2AALDH1A1CNR1 | |
| SCHEMBL11236184 | 0.84 | NPC1 (0.50) | LMNAMEN1KMT2AALDH1A1CNR1 | |
| SCHEMBL24080891 | 0.83 | MAPT (0.47) | LMNAMEN1KMT2AALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1828 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4499765-B1 | COMPOSITIONS AND METHODS FOR TUNGSTEN ETCHING INHIBITION | BASF SE (DE) | 2026-05-06 | — | — | EP | claimed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| EP-4634964-A1 | SOLUTION FOR POST ETCH RESIDUE REMOVAL (PERR) | BASF SE (DE) | 2025-10-22 | — | — | EP | claimed |
| US-20250215266-A1 | COMPOSITIONS AND METHODS FOR TUNGSTEN ETCHING INHIBITION | BASF SE (DE) | 2025-07-03 | — | — | US | claimed |
| WO-2025088012-A1 | COMPOSITIONS AND METHODS FOR REMOVAL OF TUNGSTEN AND DIELECTRIC LAYERS | BASF SE (DE) | 2025-05-01 | — | — | WO | claimed |
| WO-2025088005-A1 | COMPOSITIONS AND METHODS FOR REMOVAL OF TUNGSTEN AND DIELECTRIC LAYERS | BASF SE (DE) | 2025-05-01 | — | — | WO | claimed |
| EP-4499765-A1 | COMPOSITIONS AND METHODS FOR TUNGSTEN ETCHING INHIBITION | BASF SE (DE) | 2025-02-05 | — | — | EP | claimed |
| WO-2024187239-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2024-09-19 | — | — | WO | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| WO-2024126588-A1 | SOLUTION FOR POST ETCH RESIDUE REMOVAL (PERR) | BASF SE (DE) | 2024-06-20 | — | — | WO | claimed |
| WO-2004066910-A2 | CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF | GLENMARK PHARMACEUTICALS LTD. (US) | 2004-08-12 | — | — | WO | claimed |
| EP-1416914-A1 | EXPANDABLE GASTRIC RETENTION DEVICE | The State of Oregon acting by and through The State Board of Higher Education on behalf of Oregon State University (US) | 2004-05-12 | — | — | EP | claimed |
| WO-2003015745-A1 | EXPANDABLE GASTRIC RETENTION DEVICE | THE STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY (US) | 2003-02-27 | — | — | WO | claimed |
| US-6291488-B1 | ADMINISTERING 2-(4-(4-CHLOROPHENYL)CYCLOHEXYL)-3-HYDROXY-1,4-NAPHTHOQUINONE AND 1-(4-CHLOROPHENYL)-5-ISOPROPYLBIGUANIDE HYDROCHLORIDE IN A RATIO OF 1:1 TO 3:1. | GLAXO WELLCOME INC. | 2001-09-18 | — | — | US | claimed |
| US-6166046-A | A SYNERGISTIC MIX RATIO | GLAXO WELLCOME INC. (US) | 2000-12-26 | — | — | US | claimed |
| US-5998449-A | MALARIA | GLAXO WELLCOME INC. (US) | 1999-12-07 | — | — | US | claimed |
| EP-0617611-B1 | ORAL OSMOTIC DEVICE | ALZA CORP (US) | 1996-01-31 | — | — | EP | claimed |
| EP-0617611-A1 | ORAL OSMOTIC DEVICE. | ALZA CORP (US) | 1994-10-05 | — | — | EP | claimed |
| WO-1993011748-A1 | ORAL OSMOTIC DEVICE | ALZA CORPORATION (US) | 1993-06-24 | — | — | WO | claimed |
| US-5200194-A | Oral osmotic device | ALZA CORPORATION (US) | 1993-04-06 | — | — | US | claimed |